Podcast Episode
Beyond COVID-19 vaccines, the centre will also support research into mRNA applications for cancer, rare diseases, and immune disorders, positioning the UK as a global hub for next-generation medicine.
The contrast is stark: while the US market contracts under anti-vaccine policies, the UK is doubling down on mRNA technology as a cornerstone of national health security. The Harwell facility joins similar Moderna plants in Australia and Canada as part of a global manufacturing network designed for rapid response to future health emergencies.
UK Greenlights First Home-Grown mRNA Vaccine in Pandemic Preparedness Push
February 11, 2026
Audio archived. Episodes older than 60 days are removed to save server storage. Story details remain below.
Britain's medicines regulator has approved the first mRNA vaccine manufactured on UK soil. Moderna's COVID-19 Spikevax vaccine will be produced at a new Oxfordshire facility capable of making up to 250 million doses during a pandemic, marking a major milestone in the country's health security strategy.
Britain Becomes mRNA Manufacturer
The UK's Medicines and Healthcare products Regulatory Agency has approved the first mRNA vaccine to be manufactured entirely on British soil, a landmark moment for the country's pandemic preparedness. Moderna's COVID-19 Spikevax LP.8.1 vaccine will now be produced at the Moderna Innovation and Technology Centre in Harwell, Oxfordshire, and supplied directly to this year's NHS vaccination campaign.A Billion-Pound Bet on British Science
The approval is the culmination of a 10-year strategic partnership between Moderna and the UK government, managed by the UK Health Security Agency. Under the deal, Moderna has committed over one billion pounds in UK research and development. The Harwell facility, which officially opened in September 2025, supports around 150 highly skilled jobs and can produce up to 100 million vaccine doses annually, with surge capacity reaching 250 million doses in a pandemic scenario.Beyond COVID-19 vaccines, the centre will also support research into mRNA applications for cancer, rare diseases, and immune disorders, positioning the UK as a global hub for next-generation medicine.
A Lifeline as US Operations Stumble
The UK milestone arrives at a turbulent time for Moderna globally. In January 2026, CEO Stephane Bancel announced the company would not invest in new late-stage vaccine trials, citing growing opposition to immunisations from US officials under Health Secretary Robert F Kennedy Jr. Just days ago, the US Food and Drug Administration refused to review Moderna's application for an mRNA-based flu vaccine, despite no safety or efficacy concerns being raised. The same vaccine has been accepted for regulatory review in the European Union, Canada, and Australia.The contrast is stark: while the US market contracts under anti-vaccine policies, the UK is doubling down on mRNA technology as a cornerstone of national health security. The Harwell facility joins similar Moderna plants in Australia and Canada as part of a global manufacturing network designed for rapid response to future health emergencies.
Published February 11, 2026 at 7:39pm